Publication | Closed Access

The use of viral load as a surrogate marker in predicting disease progression for patients with early invasive cervical cancer with integrated human papillomavirus type 16

Viral LoadCervical Cancer ManagementCervical Cancer ScreeningCervical CancerDisease ProgressionHuman Papillomavirus VaccinesMedicineCancer DetectionViral DiagnosticsPathologyVirologyCytopathologyPublic HealthSurrogate MarkerOncologyViral OncologyPrecancerous LesionsCancer-associated Virus